GW&K Investment Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $141K | Sell |
5,025
-520
| -9% | -$13.8K | ﹤0.01% | 418 |
|
|
2025
Q4 | $138K | Buy |
5,545
+153
| +3% | +$3.86K | ﹤0.01% | 428 |
|
|
2025
Q3 | $137K | Buy |
5,392
+63
| +1% | +$1.55K | ﹤0.01% | 418 |
|
|
2025
Q2 | $129K | Buy |
5,329
+1,463
| +38% | +$34.1K | ﹤0.01% | 405 |
|
|
2025
Q1 | $98K | Buy |
3,866
+269
| +7% | +$7.04K | ﹤0.01% | 410 |
|
|
2024
Q4 | $95K | Sell |
3,597
-258
| -7% | -$7K | ﹤0.01% | 402 |
|
|
2024
Q3 | $112K | Buy |
3,855
+380
| +11% | +$11.1K | ﹤0.01% | 387 |
|
|
2024
Q2 | $97K | Buy |
3,475
+920
| +36% | +$25.3K | ﹤0.01% | 390 |
|
|
2024
Q1 | $71K | Sell |
2,555
-263
| -9% | -$7.3K | ﹤0.01% | 394 |
|
|
2023
Q4 | $81K | Buy |
2,818
+326
| +13% | +$9.86K | ﹤0.01% | 383 |
|
|
2023
Q3 | $83K | Buy |
2,492
+627
| +34% | +$22.2K | ﹤0.01% | 372 |
|
|
2023
Q2 | $68K | Buy |
+1,865
| New | +$72.6K | ﹤0.01% | 368 |
|
|
2022
Q3 | – | Sell |
-2,274
| Closed | -$119K | – | 716 |
|
|
2022
Q2 | $119K | Buy |
2,274
+855
| +60% | +$43.6K | ﹤0.01% | 352 |
|
|
2022
Q1 | $73K | Buy |
+1,419
| New | +$73.6K | ﹤0.01% | 365 |
|
|
2020
Q4 | – | Sell |
-628
| Closed | -$22K | – | 402 |
|
|
2020
Q3 | $22K | Buy |
+628
| New | +$22K | ﹤0.01% | 344 |
|
|
2018
Q1 | – | Sell |
-7,595
| Closed | -$261K | – | 301 |
|
|
2017
Q4 | $261K | Sell |
7,595
-292,765
| -97% | -$9.98M | ﹤0.01% | 246 |
|
|
2017
Q3 | $10.2M | Sell |
300,360
-599,066
| -67% | -$19.3M | 0.17% | 179 |
|
|
2017
Q2 | $28.7M | Buy |
899,426
+23,767
| +3% | +$750K | 0.49% | 90 |
|
|
2017
Q1 | $28.4M | Buy |
875,659
+41,184
| +5% | +$1.3M | 0.54% | 79 |
|
|
2016
Q4 | $25.7M | Sell |
834,475
-277,768
| -25% | -$8.48M | 0.5% | 83 |
|
|
2016
Q3 | $35.7M | Buy |
1,112,243
+53,138
| +5% | +$1.78M | 0.67% | 55 |
|
|
2016
Q2 | $35.4M | Buy |
1,059,105
+48,299
| +5% | +$1.54M | 0.73% | 43 |
|
|
2016
Q1 | $28.4M | Buy |
1,010,806
+44,012
| +5% | +$1.26M | 0.63% | 63 |
|
|
2015
Q4 | $29.6M | Buy |
966,794
+5,247
| +0.5% | +$165K | 0.7% | 61 |
|
|
2015
Q3 | $28.7M | Buy |
961,547
+13,377
| +1% | +$429K | 0.68% | 58 |
|
|
2015
Q2 | $30.2M | Buy |
948,170
+2,054
| +0.2% | +$66.9K | 0.69% | 53 |
|
|
2015
Q1 | $31.2M | Buy |
946,116
+45,106
| +5% | +$1.43M | 0.71% | 57 |
|
|
2014
Q4 | $26.6M | Buy |
901,010
+10,750
| +1% | +$308K | 0.64% | 65 |
|
|
2014
Q3 | $25M | Buy |
890,260
+23,431
| +3% | +$658K | 0.66% | 64 |
|
|
2014
Q2 | $24.4M | Sell |
866,829
-8,568
| -1% | -$244K | 0.62% | 68 |
|
|
2014
Q1 | $26.7M | Buy |
875,397
+13,565
| +2% | +$404K | 0.72% | 59 |
|
|
2013
Q4 | $25M | Buy |
861,832
+13,466
| +2% | +$392K | 0.68% | 59 |
|
|
2013
Q3 | $23.1M | Sell |
848,366
-117,290
| -12% | -$3.19M | 0.71% | 57 |
|
|
2013
Q2 | $25.7M | Buy |
+965,656
| New | +$26.7M | 0.95% | 33 |
|
Other funds holding PFE
VCM
VPM
GW&K Investment Management's PFE Position: Q1 2026 in Review
GW&K Investment Management reduced its Pfizer (PFE) stake by 9.4% in Q1 2026, selling an estimated $13.8K and leaving 5,025 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #418.
GW&K Investment Management first reported a position in PFE in Q2 2013 and has held it in 34 quarters since. The position peaked at $35.7M in Q3 2016. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- GW&K Investment Management held 5,025 shares of Pfizer worth $141K as of Q1 2026.
- GW&K Investment Management sold 520 Pfizer shares in Q1 2026, an estimated $13.8K.
- Pfizer made up ﹤0.01% of GW&K Investment Management's portfolio in Q1 2026, its #418 holding.
- GW&K Investment Management first reported a position in Pfizer in Q2 2013 and has held it in 34 quarters since.
- GW&K Investment Management's Pfizer position peaked at $35.7M in Q3 2016.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.